RxDoctor Payments Data

Thomas Catron, MD

Gastroenterology · Mt Juliet, TNNPI 1851787931

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 38.4% of the total. Reporting peaked in 2022 at $1,096 and has fallen 58.0% since, to $461 in 2025. That places this record below the midpoint for gastroenterology clinicians in TN, where the typical reported total is $2,975.

$2,978in general payments, 2019–2025

Across 168 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$618
  • Takeda Pharmaceuticals U.S.A., Inc.$265
  • QOL Medical, LLC$108
  • Johnson & Johnson$102
  • Madrigal Pharmaceuticals$86
  • plus $655 from 22 others

What the payments were for

  • Food & beverage$2,96099%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,978 in reported general payments places this provider in the 50th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$72,222
Medicare patients
194
Services billed
1,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide14$13,592
Colestipol Hcl23$3,144
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl88$1,423
Esomeprazole Magnesium26$976
Omeprazole72$914
Famotidine34$582
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine13$303
Dicyclomine Hcl18$248
Pantoprazole Sodium20$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,143$13,59214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Mt Juliet

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →